These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 37431661)

  • 61. Increase of vaccination coverage by mass media and individual approach: intensified measles, mumps, and rubella prevention program in Finland.
    Paunio M; Virtanen M; Peltola H; Cantell K; Paunio P; Valle M; Karanko V; Heinonen OP
    Am J Epidemiol; 1991 Jun; 133(11):1152-60. PubMed ID: 2035518
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Field evaluation of typhoid conjugate vaccine in a catch-up campaign among children aged 9 months to 15 years in Sindh, Pakistan.
    Thobani RS; Yousafzai MT; Sultana S; Kazi AM; Jan M; Rafey A; Khan A; Irfan S; Ujjan IU; Brown N; Mårtensson A; Qamar FN
    Vaccine; 2022 Aug; 40(36):5391-5398. PubMed ID: 35945044
    [TBL] [Abstract][Full Text] [Related]  

  • 63. A Phase II, Randomized, Double-blind, Controlled Safety and Immunogenicity Trial of Typhoid Conjugate Vaccine in Children Under 2 Years of Age in Ouagadougou, Burkina Faso: A Methods Paper.
    Laurens MB; Sirima SB; Rotrosen ET; Siribie M; Tiono A; Ouedraogo A; Liang Y; Jamka LP; Kotloff KL; Neuzil KM
    Clin Infect Dis; 2019 Mar; 68(Suppl 2):S59-S66. PubMed ID: 30845330
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Serogroup A meningococcal conjugate (PsA-TT) vaccine coverage and measles vaccine coverage in Burkina Faso--implications for introduction of PsA-TT into the Expanded Programme on Immunization.
    Meyer SA; Kambou JL; Cohn A; Goodson JL; Flannery B; Medah I; Messonnier N; Novak R; Diomande F; Djingarey MH; Clark TA; Yameogo I; Fall A; Wannemuehler K
    Vaccine; 2015 Mar; 33(12):1492-8. PubMed ID: 25636915
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Modeling the Transmission of Measles and Rubella to Support Global Management Policy Analyses and Eradication Investment Cases.
    Thompson KM; Badizadegan ND
    Risk Anal; 2017 Jun; 37(6):1109-1131. PubMed ID: 28561947
    [TBL] [Abstract][Full Text] [Related]  

  • 66. [Immunization Programme and Coverage against Measles and Rubella in Spain. Challenges for Achieving their Elimination].
    Limia Sánchez A; Molina Olivas M
    Rev Esp Salud Publica; 2015; 89(4):357-64. PubMed ID: 26580791
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Pediatric immunizations.
    Edwards KM
    Curr Probl Pediatr; 1993; 23(5):186-209. PubMed ID: 8354078
    [TBL] [Abstract][Full Text] [Related]  

  • 68. New and improved vaccines. Promising weapons against varicella, hepatitis A, and typhoid fever.
    Conrad DA; Jenson HB
    Postgrad Med; 1996 Oct; 100(4):113-8, 121-5, 127. PubMed ID: 8858086
    [TBL] [Abstract][Full Text] [Related]  

  • 69. The United States--The Netherlands Round Table Conference on immunization. Summary report.
    Ruitenberg EJ; Hinman AR
    Public Health Rep; 1983; 98(3):218-22. PubMed ID: 6867253
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Polio Legacy in Action: Using the Polio Eradication Infrastructure for Measles Elimination in Nigeria-The National Stop Transmission of Polio Program.
    Michael CA; Waziri N; Gunnala R; Biya O; Kretsinger K; Wiesen E; Goodson JL; Esapa L; Gidado S; Uba B; Nguku P; Cochi S
    J Infect Dis; 2017 Jul; 216(suppl_1):S373-S379. PubMed ID: 28838182
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Current immunizations for travel.
    Kirkpatrick BD; Alston WK
    Curr Opin Infect Dis; 2003 Oct; 16(5):369-74. PubMed ID: 14501987
    [TBL] [Abstract][Full Text] [Related]  

  • 72. [The new National Immunization Program 2017-2019 and the Essential Care Levels: what is going to change?].
    De Waure C; Sisti LG; Poscia A; Ricciardi W
    Ig Sanita Pubbl; 2017; 73(5):405-418. PubMed ID: 29433128
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Trend of measles-rubella vaccination coverage and impact on measles epidemiology in the Savannah Region, Ghana; 2018-2022: A secondary data analysis.
    Rockson Adjei M; Longsignikuu A; Saeed Iddris I; Nang Suuri T; Asamoah B; Okoye M; Vanessa Baafi J; Kubio C; Ohene SA; Grobusch MP
    Vaccine; 2024 Mar; 42(8):1910-1917. PubMed ID: 38365480
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Vaccine-preventable disease control in the People's Republic of China: 1949-2016.
    Yu W; Lee LA; Liu Y; Scherpbier RW; Wen N; Zhang G; Zhu X; Ning G; Wang F; Li Y; Hao L; Zhang X; Wang H
    Vaccine; 2018 Dec; 36(52):8131-8137. PubMed ID: 30497834
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Factors affecting non-coverage of measles-rubella vaccination among children aged 9-59 months in Tanzania.
    Mkopi A; Mtenga S; Festo C; Mhalu G; Shabani J; Tillya R; Masemo A; Kheir K; Nassor M; Mwengee W; Lyimo D; Masanja H
    Vaccine; 2021 Oct; 39(41):6041-6049. PubMed ID: 34531077
    [TBL] [Abstract][Full Text] [Related]  

  • 76. A mass vaccination campaign targeting adults and children to prevent typhoid fever in Hechi; expanding the use of Vi polysaccharide vaccine in southeast China: a cluster-randomized trial.
    Yang J; Acosta CJ; Si GA; Zeng J; Li CY; Liang DB; Ochiai RL; Page AL; Danovaro-Holliday MC; Zhang J; Zhou BD; Liao HZ; Wang ML; Tan DM; Tang ZZ; Gong J; Park JK; Ali M; Ivanoff B; Liang GC; Yang HH; Pang T; Xu ZY; Donner A; Galindo CM; Dong BQ; Clemens JD
    BMC Public Health; 2005 May; 5():49. PubMed ID: 15904514
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Who gets vaccinated in a measles-rubella campaign in Nepal?: results from a post-campaign coverage survey.
    Danovaro-Holliday MC; Rhoda DA; Lacoul M; Prier ML; Gautam JS; Pokhrel TN; Dixit SM; Rajbhandari RM; Bose AS
    BMC Public Health; 2022 Feb; 22(1):221. PubMed ID: 35114969
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Celebrating 50 years of polio elimination in New Zealand: but inadequate progress in eliminating other vaccine-preventable diseases.
    Wilson N; Baker MG
    N Z Med J; 2012 Nov; 125(1365):67-74. PubMed ID: 23254502
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Forecasting Demand for the Typhoid Conjugate Vaccine in Low- and Middle-income Countries.
    Debellut F; Hendrix N; Pitzer VE; Neuzil KM; Constenla D; Bar-Zeev N; Marfin A; Pecenka C
    Clin Infect Dis; 2019 Mar; 68(Suppl 2):S154-S160. PubMed ID: 30845321
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Current status of vaccine-preventable diseases.
    Witte JJ
    Postgrad Med; 1974 Oct; 56(4):55-9. PubMed ID: 4412686
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.